Prolytix, a U.S. leader in bioanalytical and protein characterization services, announced it has expanded its thrombosis and hemostasis testing offerings through the acquisition of 60 validated assays from the Hemostasis Reference Laboratory (HRL). This strategic addition positions Prolytix to deliver a more comprehensive suite of analytical services across the entire development continuum, from sample collection and research reagents to advanced clinical and translational testing.
The company has also been awarded a CLIA Certificate of Compliance, reinforcing its laboratory quality and operational rigor. The expanded capabilities support GLP, GCP, and CLIA-compliant workflows and strengthen Prolytix’s role in advancing hemostasis, thrombosis, and coagulation disorder research for biopharmaceutical sponsors.
Read the full press release here.